1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial

Autor:	Laurent Brouchet, B. Milleron, Olivier Molinier, M. Wislez, F. Le Pimpec Barthes, M.-A. Massiani, R. Caliandro, Martine Antoine, Diane Damotte, Virginie Westeel, O. Carre, J. Mazieres, T. Egenod, Gérard Zalcman, Alexandra Langlais, Radj Gervais, Armelle Lavolé, Jalal Assouad, Franck Morin, Gaelle Jeannin
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty Disease free survival Durvalumab business.industry non-small cell lung cancer (NSCLC) Pathological response Hematology medicine.disease Independent factor Internal medicine medicine Overall survival business
Zdroj:	Annals of Oncology. 32:S931
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1754
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7e9688b78de4bfcbac238a3f56cf7839 https://doi.org/10.1016/j.annonc.2021.08.1754 Zobrazit plný text záznamu